Abstract
A companion family of disclosures analyzes consumer-wearable sleep over a staging-independent in-bed window — robust overnight heart-rate variability, the same per session including naps, and the inverse movement-active "burden" read — by windowing on time-in-bed rather than the device's movement-based sleep/wake labels. None of them measures how long it takes to fall asleep. This disclosure adds sleep onset latency (SOL) to that family: per session — every night and every nap — SOL is computed as the offset from a sleep-intent anchor (the start of the in-bed window, optionally tightened by secondary cues) to the first sustained sleep onset detected from beat-to-beat and movement data, with the same confidence gating used elsewhere in the family. The signal is disclosed as two-tailed and population-aware: a long SOL is the familiar insomnia complaint, while an abnormally short SOL — and its extreme, near-zero "sleep-attack" case — is the more Parkinson's-specific read, given the documented prevalence of excessive daytime sleepiness and sudden-onset daytime sleep on dopaminergic therapy in that population. Because naps are retained as first-class sessions, the method yields a daytime SOL distribution — in the spirit of, but not equivalent to, a clinical Multiple Sleep Latency Test — that mainstream trackers, which discard or merge naps and report SOL (if at all) only as a weak nightly number, cannot produce. All outputs are framed as within-person trends, never a diagnosis or a clinical score.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
ziemski, gerard, "Per-session sleep onset latency as a two-tailed self-tracking signal in Parkinson's disease, measured across nights and naps over a staging-independent in-bed window", Technical Disclosure Commons, ()
https://www.tdcommons.org/dpubs_series/10494